MRPL10 is encoded by the MRPL10 gene (OMIM: 611825) and localizes to the mitochondrial large ribosomal subunit (39S). It plays a central role in mitochondrial protein synthesis, which is essential for producing components of the electron transport chain and ATP synthase . Unlike bacterial ribosomes, mitochondrial ribosomes in mammals have a higher protein-to-rRNA ratio (~75%) and lack 5S rRNA, making them structurally distinct .
Post-Translational Modification: MRPL10 undergoes lysine acetylation, which regulates mitochondrial translation efficiency. SIRT3, an NAD⁺-dependent deacetylase, deacetylates MRPL10 to modulate ribosomal activity .
Sequence Variability: MRPL10 exhibits low sequence homology with bacterial homologs, complicating evolutionary analyses .
In a landmark study, SIRT3 was identified as the primary deacetylase for MRPL10. Acetylation at lysine residues (K124, K162, K196) enhances ribosomal activity, while deacetylation by SIRT3 suppresses it . This mechanism links mitochondrial translation to cellular energy status via NAD⁺ levels.
Western Blot (WB):
Immunoprecipitation (IP):
Immunofluorescence (IF):
MRPL10 (mitochondrial ribosomal protein L10) is a component of the large subunit (39S) of the mitochondrial ribosome. It plays a crucial role in mitochondrial protein synthesis. Research has identified MRPL10 as the major acetylated protein in the mitochondrial ribosome, suggesting it serves as a regulatory node for mitochondrial translation . The protein has a molecular weight of 29 kDa and consists of 261 amino acids .
Methodologically, researchers studying MRPL10 function often employ techniques like RNA interference (RNAi) to deplete MRPL10 and observe effects on mitochondrial translation rates and mitochondrial function. Similar to findings with MRPL12, MRPL10 depletion may affect steady-state levels of mitochondrial transcripts .
MRPL10 antibodies are versatile tools in mitochondrial research, with validated applications including:
| Application | Typical Dilution Range | Cell/Tissue Types |
|---|---|---|
| Western Blot (WB) | 1:500-1:50000 | HEK-293, HeLa, A549, U2OS, LNCaP, Jurkat, K-562 cells |
| Immunohistochemistry (IHC) | 1:20-1:200 | Human testis tissue |
| Immunofluorescence (IF)/ICC | 1:50-1:1600 | HepG2, HeLa cells |
| Immunoprecipitation (IP) | 0.5-4.0 μg for 1.0-3.0 mg protein | Mouse liver tissue |
| ELISA | 1:1000 | Various |
| Cytometric bead array | Range: 0.098-100 ng/mL | Various |
For optimal results, researchers should perform antibody titration in each experimental system .
MRPL10 antibodies show varying species reactivity profiles depending on the manufacturer and clone. Based on validation data:
| Antibody Identifier | Host | Species Reactivity | Validation Method |
|---|---|---|---|
| 16652-1-AP (Proteintech) | Rabbit | Human, mouse, rat | WB, IHC, IF/ICC, IP |
| 68623-1-Ig (Proteintech) | Mouse | Human | WB, IF/ICC |
| ABIN3185640 | Rabbit | Human | WB, ELISA, IHC |
| HPA021234 | Rabbit | Human | WB, IF, IHC |
| NBP1-82858 | Rabbit | Human | WB, IHC, IF |
When selecting an antibody for cross-species studies, researchers should prioritize those with validated reactivity across their species of interest .
Proper storage and handling of MRPL10 antibodies is critical for maintaining their performance and extending shelf life. Based on manufacturer recommendations:
Storage temperature: Store at -20°C for long-term preservation
Buffer composition: Most MRPL10 antibodies are provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3
Aliquoting: While manufacturers indicate aliquoting is unnecessary for -20°C storage, it is recommended for antibodies that will undergo multiple freeze-thaw cycles
Stability: MRPL10 antibodies are typically stable for one year after shipment when stored properly
Working solution: When preparing diluted working solutions, use fresh buffer and store at 4°C for short-term use only
Some suppliers offer smaller (20μl) sizes containing 0.1% BSA for enhanced stability . Always consult the product-specific documentation for any special handling considerations.
Proper experimental controls are essential for validating MRPL10 antibody results:
Positive controls:
Cell lines with known MRPL10 expression: HEK-293, HeLa, A549, and HepG2 cells
Mitochondrial fraction: Enriched mitochondrial preparations from HEK-293 cells
Negative controls:
Primary antibody omission: Replacing primary antibody with same-species IgG
MRPL10 knockdown/knockout: Using siRNA or CRISPR to generate MRPL10-depleted samples
Blocking peptide: Pre-incubation of antibody with immunizing peptide to confirm specificity
Specificity validation:
Western blot should show a single band at the expected molecular weight (29 kDa)
Immunofluorescence should demonstrate mitochondrial localization pattern
Knockdown validation: Signal should decrease proportionally to protein depletion
Methodologically, researchers should include these controls in every experiment to ensure reliable interpretation of results.